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Quinoxaline 1,4-di-N-oxides (QdNOs) have manifold biological properties, including
antimicrobial, antitumoral, antitrypanosomal and antiinflammatory/antioxidant activities.
These diverse activities endow them broad applications and prospects in human
and veterinary medicines. As QdNOs arouse widespread interest, the evaluation
of their medicinal chemistry is still in progress. In the meantime, adverse effects
have been reported in some of the QdNO derivatives. For example, genotoxicity
and bacterial resistance have been found in QdNO antibacterial growth promoters,
conferring urgent need for discovery of new QdNO drugs. However, the modes
of actions of QdNOs are not fully understood, hindering the development and
innovation of these promising compounds. Here, QdNOs are categorized based
on the activities and usages, among which the antimicrobial activities are consist
of antibacterial, antimycobacterial and anticandida activities, and the antiprotozoal
activities include antitrypanosomal, antimalarial, antitrichomonas, and antiamoebic
activities. The structure-activity relationship and the mode of actions of each type of
activity of QdNOs are summarized, and the toxicity and the underlying mechanisms
are also discussed, providing insight for the future research and development of these
fascinating compounds.
Keywords: quinoxaline 1,4-di-N-oxides, antimicrobial, antitumoral, antiprotozoal, antiinflammatory, antioxidant,
structure-activity relationship, mode of action
INTRODUCTION
Quinoxaline is a heterocyclic compound containing a benzene ring and a pyrazine ring.
Oxidation of both nitrogens of the pyrazine ring to obtain QdNO offers it variety of biological
properties, including antitumoral, antibacterial, anticandida, antitrypanosomal, antiinflammatory/
antioxidant, and mutagenic properties. The versatile activities of QdNOs have aroused
Abbreviations: ADG, average daily gain; BTO, 1,2,4-benzotriazine 1,4-dioxide; BTZ, benzotriazinyl radical; CBX, carbadox;
CYA, cyadox; DMPO, 5,5′-dimethylpyrroline 1-N-oxide; DSBs, double-strand breaks; E(1)R, one electron reduction
potential; EPR, electron paramagnetic resonance; HIF, hypoxia-inducible factor; HR, homologous recombination; LOX,
lipoxygenase; MDR, multidrug resistant; MEQ, mequindox; MIC, minimum inhibitory concentration; NOAEL, no observed
adverse effect level; NOS, nitric oxide synthase; •OH, hydroxyl radical; OLA, olaquindox; O•−2 , superoxide radical; QCT,
quinocetone; QdNOs, quinoxaline 1,4-di-N-oxides; QDX, quindoxin; ROS, reactive oxygen species; SAR, structure-activity
relationship; SSBs, single-strand breaks; TB, Tuberculosis; Topo II, topoisomerase II; TPZ, tirapazamine; VEGF, vascular
endothelial growth factor; 2DE-MS, two-dimensional polyacrylamide gel electrophoresis combined with mass spectrometry.
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worldwide interests and endowed them potential application
in human and veterinary medicines. For example, the QdNO
antibacterial growth promoters have been widely used as feed
additives to prevent infectious disease and improve animal
growth since 1970s (Carta et al., 2005), and the antitumoral drug,
TPZ (3-amino-BTO 1,4 dioxide, SR4233), has been subjected to
phase II clinical trial (Covens et al., 2006; Maluf et al., 2006;
Cohen et al., 2007). Although QdNOs with other activities are
still in the research stage, they have exhibited great application
prospects.
With the wide use of QdNOs, the toxicity and drug resistance
gradually have become the disadvantages for further application
of these promising compounds. The molecular targets of
quinoxaline derivatives, which is a step beyond simply looking
at their activities, should be analyzed. Nevertheless, knowledge
about the mode of actions of QdNOs is far from clear, hindering
the development of this kind of drugs. Therefore, a detail study
on the mode of actions of QdNOs will provide information
about the drug targets and the drug action pathway(s) and be
helpful to construct models to screen new drugs. Meanwhile,
the study of SAR combined with the study of drug action
will explain the reason for that different structures of QdNOs
exhibit different activities. Furthermore, since most of the drugs
have more than one mechanism of action, the deeper study of
the drug actions may discover new drug target(s) and provide
potential approaches to conquer the problem of drug resistance
and to mitigate or avoid toxicity. In this review, the mode
of actions of QdNOs and the SAR analysis are elucidated
and updated in sort of the different biological properties,
giving insight to the future development of these fascinating
compounds.
ANTIMICROBIAL ACTIVITIES OF QdNOs
Antibacterial Activity and Bacterial
Resistance
The antibacterial activity of QdNOs was first reported in
McIlwain (1943), and subtherapeutic levels of antibacterial
QdNOs have been used for nearly 50 years to promote the
growth of animals and improve efficiency of feed conversion
in animal husbandry (Carta et al., 2005). As shown in
Figure 1, veterinary-used QdNO derivatives include (QdNOs),
OLA [2-(N-2′-hydroxyethyl-carbamoyl)-3-methyl quinoxaline
1,4-di-N-oxide firstly synthesized by Bayer in 1967], CBX
[hydrazine carboxylic acid (2-quinoxalinyl-methylene) methyl
ester 1,4-di-N-oxide firstly synthesized by Pfizer in 1968]. MEQ
(3-methyl-2- quinoxalinacetyl-1,4-di-N-oxide) and QCT (3-
methyl-2-quinoxalinbenzenevinylketo-1,4-di-N-oxide) are novel
synthetic QdNO derivatives developed by Lanzhou Institute of
Animal Husbandry and Veterinary Drugs, Chinese Academy
of Agricultural Sciences (Lanzhou, China). CYA [cyan acetic
acid (1,4-di-N-oxy-quinoxalin-2-ylmethylene] hydrazide firstly
designed by Chemapol Benelux) is a new QdNO member which
is being evaluated in clinical trials for animals in China.
Olaquindox exhibits wide spectrum of antibacterial effect,
strongly inhibiting the growth of Escherichia coli, Proteus,
Pasteurella, and dysentery spirochete (Drumev, 1981). Because
of its genotoxic potential, OLA is not permitted to use in food-
producing animals in the European Union and Canada (WHO,
1994; European Union [EU], 1998; Standing Committee for
Animal Nutrition [SCAN], 1998). CBX shows good therapeutic
effect on swine dysentery caused by Brachyspira hyodysenteriae
(Rainier et al., 1973a,b; Downing, 1974) and also has good
antibacterial effects against Salmonella, E. coli, and other Gram-
negative bacteria (Troutt et al., 1974; Das, 1984). CBX was
once used as growth-promoting feed additives for piglets or
pigs at growing phase (Yen and Pond, 1993) before it was
prohibited by the European Union [EU] (1998) because of its
mutagenic effects, developmental and reproductive toxicity and
carcinogenicity (WHO, 1991; European Union [EU], 1998). In
view of the significant effect of CBX on swine dysentery and
bacterial enteritis, the United States, Canada, and other countries
still allow it used as therapeutic agents. MEQ, which shows good
antibacterial activity against Gram-negative bacteria, especially
Salmonella, has been widely used in China as an animal feed
additive and veterinary medication for diseases, such as swine
dysentery and piglet white diarrhea (Liu et al., 2012). QCT is
active against B. hyodysenteriae, and is also effective against
Salmonella, E. coli, and other Gram-negative bacilli. In China,
QCT is used as a growth promoting agent for pigs, poultry, and
aquatic and has been approved as an animal growth promoter in
China since 2003 (Ministry of Agriculture of P. R. China, 2003).
CYA shows good antibacterial activity against Staphylococcus
hyicus, Pasteurella multocida, and E. coli (Ding et al., 2006a,b),
and also exhibits good growth-promoting effect on broilers
and swine. With good clinical safety, CYA has been regarded
as a potential replacement of OLA and CBX (Cihak and Srb,
1983).
Only a few studies have investigated the mechanism of
antibacterial action of QdNOs. Suter et al. (1978) first found the
synthesis of DNA (but not RNA and protein) was completely
inhibited by QDX in the absence of oxygen. QdNOs also
induced degradation of DNA in both proliferating and non-
proliferating cells, while strains were more resistant in the
presence of oxygen. QDX was reduced to quinoxaline-N-oxide by
the intact E. coli cells or the cell-free extract. EPR measurements
demonstrated the generation of free radicals during the reduction
of QDX. Oxygen or deficiency of energy sources impaired the
antibacterial activity and the reduction of QDX. In consistence
with Suter’s result, our group recently found that CYA also
had anaerobe-selective activity, and losing one or two of the
oxygen’s of CYA exhibited no antibacterial activity (Cheng et al.,
2015).
The ability of QDX to cleave DNA was explicitly characterized
using in vitro assays by Ganley et al. (2001). The results
evidenced that QDX was a hypoxia-selective, redox-activated
DNA-cleaving agent. The action of QDX on DNA yielded direct
strand breaks with almost no sequence specificity, consistent with
the involvement of radical species. In the absence of oxygen,
QDX (a) received an electron and a hydrogen ion to form a
neutral radical (b) (Figure 2). They considered two possibilities
about the DNA-cleaving radical resulting from redox activation
of QDX (a). First, the radical b might directly abstract hydrogen
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FIGURE 1 | Chemical structures of veterinary-used QdNO antibacterials.
FIGURE 2 | One-electron reduction of quinoxaline 1,4-dioxide by reductase (Ganley et al., 2001).
atoms from the DNA backbone, followed by elimination of water
to yield the quinoxaline monoxide (c). Alternatively, radical b
might fragment to form the known DNA-cleaving agent •OH and
monoxide c.
Early study showed that polA, recA, recB, recC, exrA, and
uvrA E. coli mutants were more susceptible to QdNOs than
the corresponding repair-proficient strains, while the QdNO
reductase activity was demonstrated to be lower in QdNO-
resistant mutants than in the susceptible parent strain (Suter
et al., 1978), indicating that QdNOs were reduced and caused
extensive DNA damage in bacterial. Recently, our group
investigated the transcriptomic and proteomic profiles of E. coli
exposed to QdNOs and found that QdNOs mainly induced
SOS response and oxidative stress (Cheng et al., 2015). We also
confirmed that ROS were induced in the QdNO-treated bacteria
and the free radical scavengers attenuated the antibacterial action
of QdNOs and DNA damage, suggesting an oxidative-DNA-
damage action of QdNOs. The QdNO radical intermediates,
likely carbon-centered and aryl-type radicals, as identified
by EPR, were the major radicals induced by QdNOs, and
xanthine oxidase was identified as one of the QdNO-activating
enzymes by using specific enzyme inhibitors (Cheng et al.,
2015).
Tirapazamine is a prodrug undergoing clinical trials for
various types of cancers (discussed in details in section
“Antitumor activity of QdNOs”). Shah et al. (2013) showed
that TPZ has antibacterial activity against E. coli, S. aureus,
and Clostridium difficile, particularly at low oxygen levels.
E. coli mutants deficient in HR were hypersusceptible to TPZ,
suggesting that drug toxicity may be due to DNA damage.
Moreover, E. coli strains deleted for genes encoding putative
reductases were resistant to TPZ, implying that these enzymes
are responsible for conversion of the prodrug to a toxic
compound.
Though the two N-oxide groups are necessary for the
antibacterial activity of QdNOs, some reduced form of
quinoxaline compounds were still reported with antibacterial
activity (Refaat et al., 2004; Singh et al., 2010, 2011). For example,
when the C2 chlorine of 2-Chloro-3-methylquinoxaline was
replaced with a benzene ring harboring an aldehyde or a free
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amino group which can be further reacted with aromatic amines
and aromatic aldehydes, this compounds also show antimicrobial
activity (Singh et al., 2010). Therefore, in addition to the N-oxide
group, the side chain of quinoxaline is another determinant of
activity.
Hansen et al. (2004) first reported the gene-encoded resistance
mechanism to OLA. In their study, two genes of oqxA and oqxB,
encoding for proteins homologous to resistance-nodulation-cell-
division family eﬄux systems, were cloned from a conjugative
plasmid isolated from E. coli. Plasmids containing the oqxAB
genes yielded high resistance to OLA and chloramphenicol in
E. coli, indicating oqxAB encodes a multidrug eﬄux pump. Later,
they demonstrated the prevalence of the OqxAB eﬄux pump by
horizontal transfer of OLA resistance from OLA-resistant isolates
using an OLA-sensitive E. coli as recipient (Hansen et al., 2005).
In addition to OLA and chloramphenicol, the OqxAB pump
conferred antimicrobial resistance or reduced susceptibility
toward a variety of substrates in E. coli, including animal growth
promoters, antimicrobials, disinfectants and detergents (Hansen
et al., 2007). Interestingly, oqxA gene was not detected in the
CYA/OLA- resistant E. coli induced in vitro (Guo et al., 2012),
suggesting there are other mechanisms conferring the bacterial
resistance.
Antimycobacterial Activity
Tuberculosis is a common, and in many cases lethal, infectious
disease caused by various strains of mycobacteria, usually
Mycobacterium tuberculosis. TB has been a companion of
mankind since the beginning of human history. In 2010, there
where 8.8 million new cases, and 1.5 million deaths, mostly in
developing countries (WHO, 2011), where more people contract
TB because of compromised immunity due to high rates of
AIDS (Lawn and Zumla, 2011). Drug-resistant TB is a public
health issue in many developing countries, as treatment of
it is longer and requires more expensive drugs. MDR TB is
defined as resistance to the two most effective first-line TB drugs,
rifampicin and isoniazid. Over the past years, QdNO derivatives
as antitubercular drug candidates hold promise in the treatment
of TB and its resistant form.
The first publication of QdNO derivatives as
antimycobacterium agents dates back to the end of the
1990s by Monge’s team (Montoya et al., 1998). Continued
identification of novel antitubercular candidates based on
their potency (MIC to H37Rv M. tb), selectivity [SI = IC50(to
VERO cell)/MIC(to H37Rv M. tb)] and low cytotoxicity make
them valid new leads for synthesizing additional analogs with
improved antitubercular activity both in vitro and in vivo.
A comprehensive review on the properties of QdNO derivatives
developed as potential antitubercular agents by Monge’s team
was reported recently (Vicente et al., 2011). As shown in
Figure 3, the QdNO antitubercular compounds can be divided
into categories based on their structures, including amide
derivatives (1–3), ketone derivatives (4–6), ester derivatives
(7–10) and other derivatives (11–12). Compounds 8 and
10, proved efficacious in vivo in a murine model of low
dose aerosol infection. Moreover, these two compounds also
showed activity against non-replicating bacteria, indicating
that QdNOs might lead to shortened therapy, because non-
replicating bacteria is believed to be a major factor responsible
for the prolonged nature of antitubercular therapy. Compound
8 is also active on single-drug resistant and MDR clinical
isolates.
In the meantime, there were other research groups studying
the antimycobacterial activity of QdNOs. As shown in Figure 4,
Zanetti’s team reported a series of 3-methylquinoxaline 1,4-
di-N-oxide derivatives with a phenylthio, phenylsulfonyl, or
phenylsulfinyl linked in R2 position of quinoxaline subunit
(Figure 4A). The series of 3-methyl-2-phenyl-thioquinoxaline
1,4-di-N-oxide derivatives presented the best MIC data,
ranging between 0.39 and 0.78 g/mL, whereas the oxidation
of sulfur bridge to yield phenylsulfinyl and phenylsulfonyl
derivatives or its replacement with benzylamino (Figure 4B) or
phenylamino group (Figure 4C) slightly reduces its activity
(Carta et al., 2002, 2004). Furthermore, 1 mg/L of 6,7-
difluoro-3-methyl-2-(3,4-dimethoxyphenylthio) quinoxaline
1,4-dioxide (Figure 4D) exhibited good activity in mouse
macrophages infected by M. avium paratuberculosis (Zanetti
et al., 2005).
Gambino’s team has devoted to the synthesis and biological
assessment of a large amount of QdNO derivatives complexed
with metals, including palladium (Pd; Urquiola et al., 2009)
and copper (Cu; Torre et al., 2005; Urquiola et al., 2008)
with antitumoral activity, vanadium (Vo) with antitrypanosomal
(Urquiola et al., 2006), insulin-mimetic (Noblia et al., 2006),
and antitumoral activities (Vieites et al., 2006), and iron
(Fe) with antimycobacterial activity (Tarallo et al., 2008,
2010). Two novel iron complexes, [Fe(L3)(3)] (L3: R1 = Cl,
R2 = OCH3) and [Fe(L4)(3)] (L4: R1 = H, R2 = CF3;
Figure 4E) showed in vitro growth inhibitory activity on
M. tuberculosis H(37)Rv (MIC = 0.78 µg/mL), together
with very low unspecific cytotoxicity on murine cell line
J774. Both complexes showed higher inhibitory effects on
M. tuberculosis than the second-line therapeutic drugs (Tarallo
et al., 2010).
Structure-activity relationship suggests that the 1,4-di-N-
oxide groups in quinoxaline ring are important to increase the
antimycobacterial activity (Montoya et al., 1998; Ortega et al.,
1999; Sainz et al., 1999). Quinoxaline-2-carbonitrile derivatives
has good antimycobacterial activity but appeared to be quite
toxic (Ortega et al., 2001, 2002); thus, the replacement of
the carbonitrile group with a carboxamide (Zarranz et al.,
2003), acetyl, benzoyl (Jaso et al., 2003), or carboxylate
groups (Jaso et al., 2005) was proposed. Among the 6(7)-
substituted quinoxaline-2-carboxylate 1,4-dioxide derivatives,
anti-TB activity principally depends on the substituents in
the carboxylate group, improving in the following order:
benzyl > ethyl > 2-methoxyethyl > allyl > tert-butyl, and
the presence of a chloro, methyl, or methoxy group in
position 7 of the benzene moiety reduces the MIC and IC(50)
values (Jaso et al., 2005). Recently, a research employed 3D-
QSAR and docking analysis to identify molecular structural
features required for effective antimycobacterial activity of
quinoxaline-2-carboxamide 1,4-di-N-oxide derivatives inside the
active site of the Mycobacterium DNA gyrase B subunit,
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FIGURE 3 | General structures of QdNO derivatives with antimycobacterial activity published by Monge’s team [modified from Vicente et al. (2011)].
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FIGURE 4 | General structures of QdNOs with antimycobacterial activity published by Zanetti’s (A–D) and Gambino’s teams (E).
and the obtained binding mode was as same as that of
the novobiocin X-ray structure (Radwan and Abdel-Mageed,
2014).
Antifungal Activity
Candida is a genus of yeasts, some of which can cause disease,
for example, Candida albicans cause infections (candidiasis or
thrush) in humans and other animals. In healthy individuals,
these infections can be cured with topical or systemic
antifungal medications (commonly over-the-counter treatments
like miconazole or clotrimazole), while in debilitated or
immunocompromised patients, candidiasis may become a
systemic disease.
Carta et al. (2002, 2004) reported the in vitro anticandida
activity (against C. albicans, C. glabrata, C. krusei, and
C. parapsilosis clinical isolates) of 3-methylquinoxaline
1,4-dioxide derivatives, in particular 2,7-dichloro-3-methyl-
quinoxaline 1,4-dioxide (Figure 5A) and 2-chloro-7-ethoxy-
6-fluoro-3-methylquinoxaline 1,4-dioxide were the most
active against C. Krusei, exhibiting MICs of 0.4 and 1.9 g/mL,
respectively (miconazole MIC= 0.9 g/mL). Murthy et alreported
one of the 2,3-diphenyl quinoxaline 1,4-dioxide derivatives
(Figure 5B) as a fruitful matrix for further biological evaluation
based on its wide zones of inhibition against C. albicans and
S. cerevisiae (Murthy et al., 2011).
FIGURE 5 | General structures of QdNOs with antifungal activity.
ANTITUMOR ACTIVITY OF QdNOs
It has been recognized for more than 50 years that very low
levels of oxygenation (hypoxia) protect cells from killing by
X-irradiation. Hypoxic cells, which are resistant to radiotherapy,
are present in solid tumors but not in normal tissues, therefore
become a major problem for radiation therapy of tumors.
Additionally, hypoxic cells are non-proliferating which do not
respond to drugs active against only proliferating cells, and
are distant from the blood vessels carrying the drug. Thus the
development of drugs with selective toxicity toward hypoxic
cells is a key objective in anticancer chemotherapy. The recent
development of QdNOs that are non-toxic until they are activated
in the hypoxic cell opens a new era.
Tirapazamine (Zeman et al., 1986) (Figure 6A), which actually
belongs to BTOs, is the first drug that has been shown to be
an efficient and selective cytotoxin for hypoxic cells. TPZ has
been subjected to phase II testing in patients with head, neck,
and gynecological cancers (Covens et al., 2006; Maluf et al., 2006;
Cohen et al., 2007).
In addition to TPZ, many research teams have been devoted
to the synthesis and development of QdNO antitumoral drugs.
Monge et al. (1995b) synthesized a series of 3-aminoquinoxaline-
2-carbonitrile 1,4-di-N-oxides (Figure 6B) with a range of
electron-donating and -withdrawing substituents in the 6-
and/or 7- positions and evaluated for toxicity to hypoxic cells.
As the electron-withdrawing nature of the 6(7)-substituent
increases, the reduction potential becomes more positive and
the compound is more readily reduced. The most potent
cytotoxins were the 6,7-dichloro and 6,7-difluoro derivatives,
which were 30-fold more potent than TPZ. The compound 7-
(4-nitrophenyl)-2-quinoxalinecarbonitrile 1,4-di-N-oxide
(Figure 6C) is 150-fold more potent than TPZ, demonstrating
that the amino group in three position is not necessary for
activity (Monge et al., 1995a). Meanwhile, they developed
two derivatives bearing a basic side chain. The 7-choloro-
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FIGURE 6 | QdNOs with hypoxia-selective and antitumoral activities.
and 7-trifluoromethyl 3-(dimethylaminopropyl) amino-2-
quinoxalinecarbonitrile 1,4-dioxide (Figure 6D) showed high
potency and excellent selectivity (Monge et al., 1995a). They
further studied the activity of the basic chain in 3 position of
the 2-quinoxalinecarbonitrile 1,4-dioxides and showed that the
replacement of (N,N-dialkyl amino) alkyl amino chain with
aromatic rigid moieties (anilines and arylpiperazines) in three
position held the potency but reduced the hypoxia-selectivity
(Ortega et al., 2000). Continuingly, they synthesized a new series
of 2-alkylcarbonyl and 2-benzoyl-3-trifluoromethylquinoxaline
1,4-di-N-oxide (Figure 6E) and evaluated for in vitro antitumor
activity against MCF7 (breast), NCI-H460 (lung), and SF-268
(central nervous system) cells. In general, anticancer activity
depends on the substituents in the carbonyl group, improving in
the order: ethyl< isopropyl< tert-butyl< phenyl-ones (Zarranz
et al., 2004). By comparison of the 1H NMR spectra, Solano
et al. (2007) also showed that the best activity was observed in
derivatives with electron-withdrawing groups in position 6 or
7 on the quinoxaline ring whereas loss of one or two oxygens
reduced the cytotoxicity.
Besides Monge’s team, Das et al. (2009) reported a
series of 2-(3-aryl-2-propenoyl)-3-methylquinoxaline-1,4-dioxides
(Figure 6F) could reverse the MDR properties of murine
L-5178Y leukemic cells which were transfected with the human
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MDR1 gene. Ismail et al. (2010) evaluated antitumor activity
of a new series of QdNOs against liver carcinoma (Hepg2)
and brain tumor (U251) human cell line, and compound 4
(Figure 6G) was the most potent hypoxia selective-cytotoxin
on EAC cell line (Ismail et al., 2010). Urquiola et al. (2009)
synthesized four new palladium(II) complexes with the formula
Pd(L)(2) (Figure 6H), where L were quinoxaline-2-carbonitrile
1,4-di-N-oxide derivatives, and evaluated their cytotoxicity
on V79 cells. Pd(L1)(2) and Pd(L2)(2), where L1 was 3-
aminoquinoxaline-2-carbonitrile 1,4-di-N-oxide and L2 was
3-amino-6(7)-methylquinoxaline-2-carbonitrile 1,4-di-N-oxide,
showed non-selective cytotoxicity. Pd(L3)(2), where L3 was
3-amino-6(7)-chloroquinoxaline-2-carbonitrile 1,4-di-N-oxide,
resulted in vitro more potent cytotoxin in hypoxia than the
corresponding free ligand and TPZ. Pd(L2)(2) introduced a
scission event in supercoiled DNA, yielding the circular relaxed
form. Meanwhile, both Pd (L1)(2) and Pd(L3)(2) produced the
loss of negative supercoils, rendering a family of topoisomers
with reduced electrophoretic mobility. For the highest doses
assayed, Pd(L3)(2) was even able to introduce positive supercoils
on the plasmid DNA (Urquiola et al., 2009).
Although TPZ has attractive features of targeting hypoxic cells
in tumors, it has limited clinical activity, in part because of poor
extravascular penetration. Hicks et al. (2010) used a spatially
resolved pharmacokinetic/pharmacodynamic model to guide the
progression of 281 TPZ analogs through a hierarchical screen.
SN29751 (Figure 6I) and SN30000 (Figure 6J) were identified
as the most promising hypoxic cytotoxins, and SN30000, in
particular, showed higher hypoxic potency and selectivity than
TPZ in tumor cell cultures and faster diffusion through HT29 and
SiHa multicellular layers.
QdNO-Induced Radicals
The mode of action of QdNO antitumoral drugs was most
comprehensively studied in TPZ. As shown in Figure 7, it is
known that TPZ (1) is an excellent substrate for a variety of
intracellular reductases that add an electron to the drug to
form an radical anion (2) (Brown, 1999), which then receives a
proton to form a neutral radical (3). This neutral radical itself
or produces other active radicals to abstract hydrogen from
DNA, producing both SSBs and DSBs, resulting in chromosome
breaks (Wang et al., 1992). Under aerobic conditions, oxygen can
remove the additional electron from the radical anion (2), thereby
back-oxidizing it to the non-toxic parent with a concomitant
production of O•−2 (Lloyd et al., 1991). Thus, the differential
hypoxic cytotoxicity results from the fact that the TPZ radical is
much more cytotoxic than the O•−2 .
There have been a number of suggestions about the identity
of active radicals produced by TPZ. An early proposal was that
the •OH radical was released from the protonated anion (3),
and the monoxide of TPZ (4) was produced simultaneously
(Laderoute and Rauth, 1986), but this was later rejected in favor
of the protonated radical anion itself as being the active species
(Laderoute et al., 1988). Release of an •OH radical has been
favored by other research workers, based on the similarity in
the spectrum of products arising from TPZ-mediated damage to
both purine and pyrimidine bases and deoxyribose sugars when
compared with damage arising from the •OH radical, although
TPZ-mediated damage exhibited some preference for purine over
pyrimidine damage (Kotandeniya et al., 2002; Birincioglu et al.,
2003; Chowdhury et al., 2007). Additionally, an EPR study using
DMPO as a spin trap reported a composite spectrum of both a C-
centered and an OH-adduct, DMPO-OH (Patterson and Taiwo,
2000), supporting evidence for the release of an •OH radical.
In contrast, Shinde et al. (2009, 2010) could not find any
evidence that •OH is eliminated from TPZ following enzymatic
reduction. They presented that the protonated radical anion (3)
undergoes dehydration to the BTZ (5) (Shinde et al., 2009),
causing oxidative damage to DNA and to oxidize TPZ itself
(Anderson et al., 2003a,b, 2006). In situ EPR measurement
confirmed that a multi N-centered radical, consistent with the
BTZ radical (5), was formed (Shinde et al., 2009). Similarly,
the one electron reduction potentials [E(1)R] of the BTZ
radicals (5) also tracked the hypoxic cytotoxicity to human
tumor cells in a series of BTO analogs of TPZ (3-amino
BTO; Anderson et al., 2005). However, although the E(1)R
value for the BTZ radical (5) of TPZ, 1.31 V (Anderson
et al., 2003b), is sufficient to oxidize the purine bases of
DNA, but not to directly oxidize the pyrimidine bases of
DNA. Later, they trapped TPZ and a series of 3-substituted
analogs by N-tert-butyl-R-phenylnitrone and observed by EPR
the formation of their aryl (phenyl) radicals (6), which is
stronger oxidants than the BTZ radical (5) (Shinde et al.,
2010).
There are still some questions whether protonated radical
anion (3) will undergo N–OH homolysis to its monoxide (4) and
•OH, or alternatively, radical anion (2) may react by dehydration
and form aminyl radicals (5) and H2O or phenyl radicals (6)
and H2O. Recently, Yin et al. (2012) discovered that dehydration
might be the result of a two-step sequence that involved N–OH
homolysis and formation of •OH aggregates of the monoxide (4)
followed by H-abstraction within the •OH aggregates to form
hydrates of aminyl (5) or of phenyl (6) radicals (Figure 7, dashed
arrows).
Electron paramagnetic resonance experiments indicate
both an aryl-type radical and an oxidizing radical, trapped as
a carbon-centered radical, are formed from the protonated
radical anion of the bioreductive anticancer prodrug,
SN30000 (Anderson et al., 2014). The carbon-centered
radical, produced upon the one-electron oxidation of the
2-electron reduced metabolite of SN30000, oxidizes 2-
deoxyribose, leads to double strand breaks. Hunter et al.
(2014a) found hypoxia-activated prodrugs of DNA-damaging
cytotoxins (TPZ, SN30000) might inhibit growth of triple-
negative breast cancer (TNBC) by simultaneously addressing
the two targets, tumor hypoxia and derangement of HR
repair.
Recently, Yadav et al. (2014) found The •OH radical was
released from 3-trifluoromethyl-quinoxaline 1,4-dioxides upon
one-electron reduction by cytochrome P450 oxidoreductase.
This process effectively competes with back oxidation of the
intermediate radical anion by oxygen and underlies the increased
aerobic cytotoxicity of such compounds compared to that seen
for, TPZ.
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FIGURE 7 | Bioreduction of TPZ with produced free radicals based on Shinde et al. (2010) and Yin et al. (2012).
Reductase
Another major unresolved question is the identity of the
enzyme(s) that activates a QdNO to cause cell death. Numerous
enzymes, including xanthine oxidase (EC 1.2.3.1; Laderoute et al.,
1988), cytochrome P450 (Wang et al., 1993), DT-diaphorase
(EC 1.6.99.2; Patterson et al., 1994), and NADPH:cytochrome
P450 reductase (EC 1.6.2.4; Patterson et al., 1995), are
able to metabolize TPZ in vitro under hypoxic conditions.
A correlation between NADPH:cytochrome P450 reductase level
(Patterson et al., 1997) or NOS (Chinje et al., 2003) level
and sensitivity to TPZ has been reported. For a long time,
there was no agreement as to which enzyme(s) are involved
in the DNA damage until Evans et al. (1998) showed that
TPZ was metabolized to DNA-damaging radicals by intra-
nuclear enzymes. TPZ radicals formed outside nuclei do
not contribute to intranuclear DNA damage, and the 80%
of the drug metabolism that occurs in the cytoplasm is
probably irrelevant for hypoxic killing effect of this drug. Later,
Delahoussaye et al. (2001) demonstrated that multiple reductases
in the nuclear matrix metabolized TPZ under hypoxia. DNA
SSBs were probably caused by the most abundant source of
reductase in the nucleus, while DNA DSBs were formed by
an unknown nuclear reductase requiring only NADPH for its
activity.
Hunter et al. (2014b) observed that forced expression
of FAD-dependent oxidoreductase domain containing 2
(FOXRED2) increased activation of hypoxia-targeted prodrugs
TPZ and SN30000. They also identified the flavoprotein P450
(cytochrome) oxidoreductase, which is responsible for prodrug
activation during hypoxia, as the predominant determinant of
sensitivity to SN30000 (Hunter et al., 2015).
Topoisomerase and Polymerase β
Topoisomerase II is essential in mammalian cells, because it
resolves the unfavorable topological structures in DNA during
replication and transcription. Drugs that stabilize Topo II with
a DNA DSB to form cleavable complex are termed Topo II
poisons (Pommier et al., 2010). Since TPZ produces a marked
inhibition of DNA replication in the nuclear matrix (Peters
et al., 2001), and TPZ-induced DNA DSBs are protein-associated
(Olive, 1995; Siim et al., 1996), Peters and Brown (2002)
considered TPZ might poison Topo II. They found under hypoxic
conditions, the nuclear extracts from LXFL 529 human lung
carcinoma cells treated with TPZ reduced the activity of Topo
II. Inhibitors of the Topo II catalytic cycle abrogated TPZ-
generated DNA DSBs and cytotoxicity, and TPZ stabilized DNA
Topo II cleavable complexes (Peters and Brown, 2002). Using
Saccharomyces cerevisiae as a model, overexpression of TOP2
(encoding Topo II) leads to hypersensitivity to TPZ, suggesting
that Topo II is also a target of TPZ in yeast (Hellauer et al., 2005).
XK469 (NSC 697887) and CQS (NSC 339004), two synthetic
quinoxaline derivatives without two oxygens on the quinoxaline
ring, also show solid tumor selectivity. XK469 and CQS have
entered Phase I and Phase II clinical study, respectively (Miller
et al., 1997; Bekaii-Saab et al., 2006; Alousi et al., 2007). Gao
et al. (1999) reported the primary target of XK469 is Topo IIβ,
and CQS was found to be both a Topo-IIα and a Topo-IIβ
poison (Gao et al., 2000). The large aromatic side chains of
XK469 and CQS can not be ignored to the drug action. Except
for TopII, TPZ also induces other DNA-protein cross-links,
including DNA-Topo I cleavable complexes (Evans et al., 2008)
and DNA-Polβ cross-link with the lesion (Sung and Demple,
2006).
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Evans et al. (2008) further showed an overall model of
TPZ damage in which DNA SSBs, base damage, and DNA-
protein cross-links (including Topo I and II cleavable complexes)
produced stalling and collapse of replication forks. The resolution
of the complex required HR and XPF/ERCC1 protein for their
repair. Cells defective in HR proteins were particularly sensitive
to TPZ, and extensive sister chromatid exchanges occurred after
treatment with TPZ. In addition, TPZ preferentially kills mutants
both with defects in XPF/ERCC1 and base excision repair. H2AX,
an indicator of DNA DSBs, is induced preferentially in cells in the
S phase of the cell cycle.
In a dose-dependent fashion, polymerase β DNA-protein
cross-links (Polβ-DPC) were detected in MDA-MB-231 human
cells treated with the antitumor drug TPZ (much more Polβ-DPC
under 1% O2 than under 21% O2; Quinones et al., 2015).
Mouse embryonic fibroblasts challenged with TPZ also incurred
Polβ-DPC.
Hypoxia-Inducible Factor 1
Hypoxia-inducible factor 1, a heterodimeric transcription factor
that mediates the adaptation of tumor cells and tissues to the
hypoxic environment, has attracted considerable interest as a
potential therapeutic target. The subunit 1α of HIF plays an
essential role in the transcriptional activation of genes involved
in tumor angiogenesis invasiveness and metastasis with its
downstream target, VEGF (Carmeliet et al., 1998).
Quinoxaline 1,4-di-N-oxides could reduce the expression
of HIF-1α mRNA in T-84 cells, and 2-benzoyl-3-phenyl-
6,7-dichloroquinoxaline 1,4-dioxide (DCQ) is shown most
effective in decreasing the HIF-1α mRNA and protein levels
(Diab-Assef et al., 2002). A hypoxic cytotoxin, 3-amino-
2-quinoxalinecarbonitrile 1,4-dioxide (TX-402), which is an
improved analog of TPZ, has been shown to inhibit HIF-1α
expression (Nagasawa et al., 2003). Recently, it is found that TPZ
acts in a novel manner to inhibit HIF-1α accumulation, in which
HIF-1α translational regulation is involving, dependent on the
phosphorylation of translation initiation factor 2a (eIF2a; Zhang
et al., 2010).
Weng et al. (2011) showed that suppression of
HIF-1α by 3-(4-Bromophenyl)-2-(ethylsulfonyl)-6-methyl-
quinoxaline 1,4-dioxide (Q39) resulted in a drastic decrease
in VEGF expression. Unlike TPZ, suppression of HIF-
1α accumulation by Q39 correlated with prominent
dephosphorylation of mTOR (mammalian target of
rapamycin) and initiation factor 4E-binding protein 1 at
the translational level. 3-[2-hydroxyethyl(methyl)amino]-2-
quinoxalinecarbonitrile 1,4-dioxide (TX-2098) was also shown
to have antitumor effect in pancreatic cancer, through inhibiting
VEGF and HIF-1α targeted gene expression (Miyake et al.,
2012). Recently, it is demonstrated that DCQ blocks breast
cancer metastasis by targeting the HIF-1 pathway (Ghattass
et al., 2014). Cancer cell death was associated with an increase
in ROS independently of p53 and was inhibited by antioxidants.
DCQ-induced ROS was associated with DNA damage, the
downregulation of HIF-1α, and inhibition of VEGF secretion.
In MCF-7 (p53 wildtype), HIF-1α inhibition was partially via
p53-activation and was accompanied by a decrease in p-mTOR
protein, suggesting interference with HIF-1α translation. In
MDA-MB-231 (p53 mutant), DCQ reduced HIF-1α through
proteasomal-dependent degradation mechanisms.
Combinational use of TPZ with other inhibitors represents
a novel mechanism for targeting tumor. In combination with
TPZ, topoisomerase I inhibitors exhibited synergistic cytotoxicity
and induced significant apoptosis in several hepatocellular
carcinoma cell lines (Cai et al., 2014). The enhanced apoptosis
induced by TPZ plus SN-38 (the active metabolite of irinotecan)
was accompanied by increased mitochondrial depolarization
and caspase pathway activation. The combination treatment
dramatically inhibited the accumulation of HIF-1α protein,
decreased the HIF-1α transcriptional activation, and impaired
the phosphorylation of proteins involved in the HR repair
pathway, ultimately resulting in the synergism of these two drugs.
TPZ mediates central vascular dysfunction in tumors and is
also a competitive inhibitor of NOS. Baker et al. (2013) further
investigated the vascular-targeting activity of TPZ by combining
it with NOS inhibitor L-NNA, or with low oxygen content gas
breathing. Irreversible loss of perfusion and enhanced tumor cell
death was observed when TPZ was combined with either low
oxygen or a NOS inhibitor, illustrating a novel use of hypoxia-




Trypanosoma cruzi is the haemoflagellate protozoan that causes
the Human American trypanosomiasis, or Chagas disease,
representing a relevant health problem in Central and South
America. The acute form of Chagas disease usually goes
unnoticed and may present as a localized swelling at the
site of entry. The chronic form may develop 10 to 20 years
after infection, which affects internal organs (e.g., the heart,
the esophagus, the colon, and the peripheral nervous system),
sometimes causing death to affected people from heart failure.
The first line of treatment is nifurtimox and benznidazole.
Cerecetto’s team (Cerecetto et al., 1999) firstly noticed QdNO
derivatives had antitrypanosomal activity against epimastigote
forms of T. cruzi. They reported a vanadium complexe of
QdNO, [V(IV)O(L)(2)], where L were 3-aminoquinoxaline-2-
carbonitrile 1,4-di-N-oxide derivatives (Figure 8A), was provide
with excellent antitrypanosomal activity, similar to that of the
reference drugs nifurtimox and benznidazole and higher than
that of the corresponding free ligands. The antitrypanosomal
activity of these vanadium complexes could be explained on
the basis of their lipophilicity and the electronic characteristics
of the quinoxaline substituents (Urquiola et al., 2006). They
also reported two QdNO compound, R3 = methyl (SI > 53.3,
selectivity index = ID50(macrophage)/ID50(T. cruzi)) and
R3 = phenyl (SI > 33.3; Figure 8B), displayed excellent
parasite/mammal selectivity indexes. Those compounds are able
to accumulate squalene suggesting that anti-T. cruzi mechanism
of action is not involved the inhibition of sterol biosynthesis
(Gerpe et al., 2010).
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FIGURE 8 | QdNOs with antitrypanosomal activity.
Monge’s team also found that QdNO derivatives presented
good inhibitor activity to the growth of T. cruzi in in vitro
assays, among which a QdNO derivative (Figure 8C) were
the most cytotoxic compounds against the protozoan, and the
IC50 were of the same order of that of nifurtimox (Aguirre
et al., 2004). The authors reported some SAR deductions: the
presence of a halo-substituent (electron-withdrawing) at benzene
moiety of quinoxaline produces more active compounds; more
hydrophilic compounds decrease the antitrypanosomal activity;
a reductive metabolism could be implicated in the mechanism of
action. Later, they prepared a series of heterocyclic-2-carboxylic
acid (3-cyano-1,4-di-N-oxidequinoxalin-2-yl)amide derivatives
(Figure 8D), among which compounds (R6 = F, R7 = F, X = O)
and (R6 = F, R7 = F, X = S; Figure 8D) presented IC50 values
in the same order as nifurtimox (Ancizu et al., 2009). Recently,
they synthesized a series of 3-trifluoromethyl QdNOs, among
which derivatives possessing electron-withdrawing substituents
in the 2-, 3-, 6-, and 7-positions were the most active compounds
(Benitez et al., 2011). One 3-trifluoromethyl QdNO compound
(Figure 8E), which was substituted with fluoro groups at the
6- and 7-positions of the quinoxaline ring, was the most active
(IC50 = 0.4 µM) and selective (SI = 10) in the cytotoxicity
assay (Torres et al., 2013). It is demonstrated that inhibition of
mitochondrial dehydrogenases are involved in the anti-T. cruzi
activity of the most active derivatives (Benitez et al., 2011; Torres
et al., 2013).
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Leishmaniasis is a parasitic disease which appears in visceral,
cutaneous and mucocutaneous forms affecting millions of people
throughout the world. Monge’s team tested pyrazole quinoxaline
derivatives against Leishmania peruviana. 2,6-dimethyl-3-f-
quinoxaline 1,4-dioxide (Figure 8F) was the most active
compound of this series against L. peruviana (IC50 = 8.9 µM;
Estevez et al., 2011). This compound resulted non-toxic for
Vero and LLc-Mk2 cells, and was almost 6 to 13 times more
active on Leishmania than on THP-1 or MPM. According
to the study of Barea et al. (2012), piperazine linked QdNO
(Figure 8G) emerged as the best leishmanicidal agent against
L. infantum (IC50 = 5.7 µM). Their later study indicated
that the R = cyclohexyl derivative (Figure 8H) had the best
antileishmanial activity against L. infantum (IC50 = 2.5 µM)
while the R = 3-chloropropyl derivative (Figure 8H) was the
best against L. amazonensis (IC50 = 0.7 µM; Barea et al., 2013).
Villalobos-Rocha et al. (2014) evaluated the in vitro biological
activity of 33 ethyl and methyl quinoxaline-7-carboxylate 1,4-
di-N-oxide derivatives on T. cruzi and L. mexicana, of which
M7 (Figure 8I) and E4 (Figure 8J) displayed activity against
both parasites. Compound M2 (Figure 8K) was predicted in the
docking procedure as a potential T. cruzi trypanothione reductase
inhibitor by its interaction with five residues close to the active
site of the enzyme.
Antimalarial Activity
Plasmodium falciparum is one of the species of Plasmodium
that cause malaria in humans. Malaria caused by this species
is the most dangerous form of malaria, with the highest rates
of complications and mortality. For nearly half a century,
chloroquine has been the primary therapy of choice. However,
chloroquine-resistant P. falciparum is now observed in nearly all
of the malaria-endemic regions and causes the most deadly form
of malaria. Therefore, it is necessary to develop cheaper and more
effective drugs against the parasite.
Zarranz et al. (2005) synthesized new series of 3-
arylquinoxaline- carbonitrile derivatives (Figure 9A) and tested
for their in vitro and in vivo activity against the erythrocytic
development of P. falciparum with different chloroquine-
resistance status. These series showed superior antimalarial
activity in respect to reduced quinoxaline analogs. The best
activity was observed with non-substituted QdNOs in positions
6 and 7 of the aromatic ring and with a hydrogen or chloro
substituent in para position of the phenyl group (Figure 9A).
Vicente et al. (2008) identified new compounds structurally
based on 3-phenyl-quinoxaline-2-carbonitrile 1,4-di-N-oxide
derivatives (Figure 9B) active against P. falciparum. Derivative
1 (Figure 9B, X = O, R7 = H) demonstrated high potency
[IC(50) = 0.63 mM] and good selectivity (SI = 10.35), thereby
becoming a new lead-compound. Marin et al. (2008) synthesized
derivatives of 3-trifluoromethyl-2-arylcarbonylquinoxaline
1,4-di-N-oxide (Figure 9C) and evaluated for their capacity to
inhibit the growth of chloroquine-resistant P. falciparum FCB1
strain in culture. Compound 7-chloro-2-(2-furylcarbonyl)-
3-trifluoromethyl-1,4-quinoxaline di-N-oxide (Figure 8C,
Ar = 2-Furyl, R1/R2 = Cl/H) was the most active, being almost
five times more active than chloroquine. It was also 50 times
more active against P. falciparum than toxic toward MCF7
cells. SAR showed that bioisosteric modification of phenyl
group by 2-thienyl or 2-furyl subunits, R2 position must be
free or occupied by a methyl group and R1 position must
be free or occupied by Cl, CH3, OCH3 or CF3. Barea et al.
(2011) synthesized new 3-amino-1,4-di-N-oxide quinoxaline-
2-carbonitrile derivatives as acetoxybenzamides (Figure 9D)
and sulfonamides (Figure 9E), and evaluated for their in vitro
antimalarial and antileishmanial activity. Compounds with one
halogenous group substituted in position 6 and 7 provide an
efficient approach for further development of antimalarial and
antileishmanial agents. From a series of quinoxaline analogs
of chalcones in another study, compounds 1a (IC50 = 6.2 µM;
Figure 9F) and 2a (IC50 = 5.8 µM; Figure 9G) were the
most active against FCR-3 P. falciparum (Gil et al., 2014).
SAR demonstrated the importance of an enone moiety
linked to the quinoxaline ring in the search for antimalarial
ligands.
The intracellular mechanism of the antiparasitic action
of QdNOs is barely elucidated. Recently, Brizuela et al.
(2014) shows that one QdNO-derived compound, Conoidin
A [2,3-bis(bromomethyl)-1,4-dioxide-quinoxaline] (Figure 9H),
exhibites potent lytic activity against P. falciparum and
constitutes an irreversible Peroxiredoxin-2 (Prx2) inhibitor.
Conoidin A is first shown as an inhibitor of host cell invasion
by the human pathogen T. gondii (Carey et al., 2004), and this
compound is a covalent inhibitor of T. gondii peroxiredoxin
II (Haraldsen et al., 2009). Conoidin A can also inactivate
the peroxiredoxin-1 from the human hookworm Ancylostoma
ceylanicum by alkylating or crosslinking the catalytic cysteines,
while maintaining the enzyme in the “locally unfolded”
conformation (Nguyen et al., 2013). Peroxiredoxin, a thiol-
dependent peroxidase, serves a critical role in converting ROS
signals into a cellular response. When Plasmodium sp. invades
red cells, it imports Prx2 from the host cell to the parasite cytosol
during intraerythrocytic development in an attempt to make up
for degradation of peroxides generated during cell metabolism.
Therefore, treatment of erythrocytes with Conoidin A produces
an unviable growth of the parasite inside, and enhances parasite
sensitivity to chloroquine (Brizuela et al., 2014).
Antitrichomonas Activity
Trichomoniasis is a protozoan infection of the human and
bovine urogenital tracts. Metronidazole, Tinidazole and other
nitroimidazoles are the most effective drugs, currently available
for treatment. In the early 1980s, Glazer and Chappel (1982)
reported the synthesis and the activity of a novel series of
pyrido[2,3-b]quinoxaline 5-oxides against Trichomonas foetus.
Carta et al. (2004) reported the synthesis and antitrichomonas
activity of a series of 6,7-difluoro-3-methylquinoxaline 1,4-
dioxides (Figure 10A). In particular, several 2-phenylthio
derivatives resulted 20- to 30-fold more potent than the reference
drug Metronidazole activity against T. vaginalis (SS22) in vitro,
isolated in Italy from a case of acute vaginal trichomoniasis. For
example, sulfoxide derivative (Figure 10B) was reported to be
more effective than the reference drug metronidazole against
T. vaginalis while one compound (Figure 10C) inhibited the
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FIGURE 9 | QdNOs with antimalarial activity.
FIGURE 10 | QdNOs with antitrichomonas activity.
growth of T. vaginalis at MIC value of 6.25 mg/mL, after 24 h
of incubation.
Antiamoebic Activity
Amebiasis is a protozoan infection of human gastrointestinal
tract caused by Entamoeba histolytica which results in 500 million
cases and approximately 110,000 deaths annually. Out of a new
series of ethyl and methyl quinoxaline-7-carboxylate 1,4-di-N-
oxide derivatives synthesized by Duque-Montano et al. (2013),
thiophene bearing motif (Figure 11A; IC50 = 0.35 µM) stood
out, having enhanced biological activity which was 11-fold higher
than others but having selectivity index [IC50 (VERO cells)/IC50
(E. histolytica)] of 16.74. Compounds T-001 (Figure 11B) and
T-016 (Figure 11C) showed IC50 values of 1.41 and 1.47 µM,
respectively, with a value of selectivity index > 60.
ANTIINFLAMMATORY AND
ANTIOXIDANT ACTIVITIES OF QdNOs
Arachidonic acid metabolism, mediated by the LOX enzyme
family, leads to the generation of leukotrienes, a type of
pro-inflammatory mediator involved in processes such as
fever, asthma, or cardiovascular disease. Additionally, aberrant
arachidonic acid metabolism is related to carcinogenesis.
For example, increased LOX expression levels have been
found in a wide range of cancers, including pancreatic,
bladder, and breast cancer (Hofmann and Steinhilber, 2013).
During the inflammation process, phagocytic leukocytes produce
ROS. A number of commercially available non-steroidal
antiinflammatory drugs, such as acetaminophen, salicylates,
C D E
FIGURE 11 | QdNOs with antiamoebic activity.
indomethacin, and nimesulide, have been shown to possess
radical scavenging properties. Therefore, the development of
new compounds having both antiinflammatory and antioxidant
activities and being LOX inhibitors is an interesting approach for
cancer prevention, treatment of chronic inflammation and other
related pathological conditions.
3-phenyl-1-(1,4-di-N-oxide quinoxalin-2-yl)-2-propen-1-
one derivatives and their 4,5-dihydro-(1H)-pyrazole analogs
were discovered to show very interesting antioxidant and
antiinflammatory properties. Compound 2a (Figure 12, series
2) displayed an in vivo antiinflammatory effect (56.1%) higher
than the reference drug, indomethacin, and promising in vitro
inhibition values of LOX (IC50 < 1 µM; Burguete et al.,
2007). Compound 7b (Figure 12, series 7) showed significant
protection against carrageenan-induced paw edema, in which
the in vivo antiinflammatory effect (41%) was similar to that of
indomethacin (47%; Burguete et al., 2011).
Burguete et al. (2011) has studied the SAR which demonstrates
that the radical scavenging ability needs a phenolic group (series
2) and/or a free amino pyrazoline ring (series 3, 8, and 10) in the
structure (Figure 12). In the presence of the pyrazoline moiety,
those with N-oxide groups in the quinoxaline ring (series 3 and
10) exhibited significantly increased reducing activity compared
to their reduced analogs (series 8), resulting in increased
scavenging activity. Compounds with an α, β-unsaturated ketone
system (1b, 2e, 4f, 5a, 5b, 5g, and 6a–f) presented the best O•−2
scavenging activities, indicating that the olefinic moiety might
play an important role in the activity by trapping the O•−2 .
The derivatives are also good •OH scavengers. In the inhibition
of LOX, the best IC50 values were shown by compounds
of series 7, 9, and compound 8f. Although compounds that
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FIGURE 12 | QdNOs with antiinflammatory and antioxidant activities [adapted from Burguete et al. (2011)].
displayed good activities of inhibition of lipid peroxidation
also presented good values of inhibition of LOX, the best
inhibitors of lipid peroxidation were those compounds without
any substitution in the quinoxaline ring while the best inhibitors
of LOX were obtained by fluoro- and methyl-substituted
derivatives.
TOXICOLOGICAL EFFECTS OF QdNOs
The toxicology effects, including short- and long-term toxicities
(Fang et al., 2006; Ihsan et al., 2010, 2011; Wang et al.,
2010, 2011a,b, 2012), genotoxicity (Ihsan et al., 2013a,b), and
photoallergic toxicity (He et al., 2006), have been extensively
studied in the veterinary-used QdNOs. The liver is the main
target organ of QdNOs, and OLA and MEQ show obvious
toxic effect on the kidney and the adrenal gland. High dose
of OLA, MEQ, CBX, and QCT can significantly inhibit the
growth and development, reproductive function and embryonic
development of rats, whereas CYA has minor effect. OLA,
CBX, and MEQ have genotoxicity, and CBX shows obvious
carcinogenic effects. QCT has certain genetic toxicity, and no
genotoxicity has been detected in CYA.
Quinoxaline 1, 4-di-N-oxides show mutagenic and DNA-
damaging effects on various organisms. Voogd et al. (1980)
reported that QDX, CAX, and OLA were mutagenic on
Saccharomyces cerevisiae, Klebsiella pneumoniae, S. typhimurium
and E. coli, causing base-pair substitutions and frame-shift
mutations. Beutin et al. (1981) found that mutagenicity of
QdNOs was dependent on the presence of N-oxide groups, since
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quinoxaline, a completely reduced derivative of QDX, was not
mutagenic, whereas the partially reduced quinoxaline-N-oxide
exhibited a lower mutagenic activity than QDX. It was suggested
that the mutagenicity of QdNOs resulted from the error-prone
repair involved in SOS responses (Nunoshiba and Nishioka,
1989). Ihsan et al. (2013a,b) compared the genotoxic potential
of QdNOs in Ames test, HGPRT gene mutation test in V79
cells, unscheduled DNA synthesis assay in human peripheral
lymphocytes, chromosome aberration test, and micronucleus
test in mice bone, and found that OLA, CBX, and MEQ were
more genotoxic than QCT and CYA. Using alkalic comet assay,
pronounced increase of DNA fragmentation were observed in
Vero cells treated with CBX, OLA, and QCT (Chen et al.,
2009). In contrast, DNA damage was significantly decreased
after incubation with S9 mix, suggesting that the intermediate
metabolites of these compounds exerted lower genotoxicity than
their parent drugs. Jin et al. (2009) also found that QCT
caused significant DNA fragment migration in a dose-dependent
manner in human hepatoma (HepG2).
The mutagenicity of QdNOs with antiparasitic activity has also
been studied. Introduction of electron-withdrawing substituents
at C-6 and/or C-7 of the quinoxaline ring enhanced in vitro
biological activity against T. cruzi. In addition, this led to the
obtainment of non-mutagenic derivatives in both the Ames
assays that were performed or their mutagenicity disappeared
when performing the assay using metabolic activation (Torres
et al., 2013). Using Ames test, Gabay et al. (2014) investigated
the mutagenicity of an in-house chemical library of eighty five
N-oxide containing heterocycles, and they found that in some
cases, a relationship was found between the presence of N-oxide
and mutagenicity, and in other cases, such as quinoxaline
dioxides with antiparasitic activity, mutagenicity was substituent
dependent.
Quinoxaline 1, 4-di-N-oxides can produce ROS and cause
oxidative cell damage. It was found that OLA induced
the increased levels of ROS and 8-OHdG in HepG2 cells,
inferring that OLA exerts genotoxic effects in HepG2 cells
probably through the ROS-induced oxidative DNA damage
(Zou et al., 2009). Using γ-H2AX as a surrogate marker for
DNA damage, Liu et al. (2012) found that MEQ treatment
induced cellular DNA damage, which paralleled the chemical-
induced elevation of ROS levels, and expression of the
antioxidant enzyme catalase partially alleviated these MEQ-
associated effects. Huang et al. (2010b) found that OLA
irritated a persistent and utmost release of ROS while
MEQ made a similar but weaker reaction. CYA, however,
had a short and unstable release of intracellular ROS. On
the other hand, quinoxalinine-2-carboxylie acid, one of the
metabolites of OLA and MEQ, did not cause any significant
production of ROS and showed relatively lower toxicity than
its parents. Zhang et al. (2014) reported that QCT damaged
the antioxidant defense abilities of HepG2 cells by reducing
the activities of endogenous antioxidant enzymes, lowering
glutathione concentration, and elevating malondialdehyde level.
One hundred and sixty QCT-responsive genes were found
to be associated with cell proliferation, glucose metabolism,
oxidative stress, and apoptosis, such as NAD(P)H dehydrogenase.
However, QCT metabolites (1,4-bisdesoxyquinocetone and 3-
methylquinoxaline-2-carboxylic acid) showed little effects on
HepG2 cells. Wang et al. (2015b) demonstrated that the rank
orders of the desoxy and bidesoxy rates in rat and pig liver
microsomes were QCT < CBX < MEQ < OLA < CYA and
QCT < MEQ < CBX < OLA < CYA, respectively. In rats,
porcine primary hepatocytes, and HepG2 cells, oxidative stress
indices and DNA damage showed inverse relationships with the
deoxidation rate, indicating that faster deoxidation of QdNOs
results in lower DNA-damage-induced toxicity.
The molecular mechanism of cell cycle arrest and apoptosis
induced by QdNOs were explored. Liu et al. (2012) report that
MEQ inhibited cell proliferation by arresting cells at the G2/M
phase of the cell cycle. Zou et al. (2011) demonstrated that OLA
induced cell cycle arrest to the S phase and dose-dependent
apoptotic cell death in HepG2 cells through a caspase-9 and -
3 dependent mitochondrial pathway. Zhang et al. (2013) found
that QCT induced apoptosis in HepG2 cells via activation of
caspase, interaction of TNF-α and TNFR1 and modulation of the
protein levels of Bid, Bax, and Bcl-2, involving the participation
of p53, p38, and JNK. c-MYC-dependent activation of the
mitochondrial apoptotic pathway may be associated with QCT-
induced toxicity (Zhang et al., 2014). Dysregulated or excessive
autophagy may lead to ‘type II programmed cell death,’ which
is closely associated with apoptosis. Zhao et al. (2015) showed
that OLA-induced autophagy in HepG2 cells is upregulated by
Beclin 1 but downregulated by ROS-dependent c-Jun N-terminal
protein kinase (JNK).
The organ toxicities of QdNOs have also been studied. Huang
et al. (2009) reported the dose-dependent long-term toxicity of
MEQ on adrenal gland in male rats, and its mechanism may
involve in oxidative stress and steroid hormone biosynthesis
pathway. Then, they found the complex interactions of MEQ
metabolism, renin–angiotensin–aldosterone system, NADPH
oxidase and oxidative stress in response to MEQ-induced tissue
toxicity and aldosterone secretion (Huang et al., 2010a). Wang
et al. (2015a) estimated the adrenal cell damage induced by
QCT and its bidesoxy-QCT (B-QCT) metabolite, and suggested
that its toxic effects resulted from N-oxide groups, and its
toxic mechanism might involve the interference of the steroid
hormone biosynthesis pathway. They also found ROS, the
Janus kinase-signal transducer and activator of transcription
(JAK/STAT) pathway, suppressors of cytokine signaling and
inflammatory cytokines (TNF-α and IL-6) were involved in
the liver and spleen toxicities of MEQ (Wang et al., 2011c).
Ihsan et al. (2011) verified that MEQ exerted testicular toxicity
by causing oxidative stress and steroidal gene expression
profiles.
PERSPECTIVES
The versatile activities of QdNOs are close related to their
chemical structures. The two N-oxide groups in the quinoxaline
ring are necessary for the antibacterial (Montoya et al., 1998;
Ortega et al., 1999; Sainz et al., 1999; Zhang, 2012), antitumor
(Solano et al., 2007), anti-Trypanosoma (Aguirre et al., 2004),
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and antimalaria (Zarranz et al., 2005) properties of QdNOs.
Some reduced forms of QdNOs, in which the two N-oxide
groups are absent, still possess biological activities. We assume
the large side chains of these reduced quinoxaline compounds
contribute more to the activities, based on the fact that in the
2-quinoxalinecarbonitrile 1,4-dioxides, the replacement of (N,N-
dialkyl amino) alkyl amino chain with aromatic rigid moieties
(anilines and arylpiperazines) in three position held the potency
but reduced the hypoxia-selectivity (Ortega et al., 2000). The
different side chains probably affect the desoxy and bidesoxy rates
of QdNOs (Wang et al., 2015b), which may result in different
levels of activities and toxicities.
For QdNO antitumoral compounds, when the electron-
withdrawing nature of the 6(7)-substituent increases, the
compound is more readily reduced and show the best
activity (Monge et al., 1995b; Solano et al., 2007). This
also is the case for antimycobacterial (Jaso et al., 2005),
antitrypanosomal (Aguirre et al., 2004; Benitez et al., 2011),
and antimalarial (Zarranz et al., 2005) activities. Interestingly,
among 2-alkylcarbonyl-3- trifluoromethylquinoxaline 1,4-
di-N-oxide derivatives, anticancer activity depends on the
substituents in the carbonyl group, improving in the order:
ethyl < isopropyl < tert-butyl < phenyl-ones (Zarranz et al.,
2004), while among 6(7)- substituted quinoxaline-2-carboxylate
1,4-dioxide derivatives, anti-TB activity depends on the
substituents in the carboxylate group, improving in the following
order: tert-butyl < allyl < 2-methoxyethyl < ethyl < benzyl
(Jaso et al., 2005). We speculate that the activity of alkyl
group substitution must be mainly affected by the substituted
carbonyl or carboxylate group, but the large benzene ring
itself may contribute more to the anticancer or anti-TB
activities.
In summary, SAR studies for QdNOs suggest that the
position C(2) of quinoxaline should be substituted by electron-
withdrawing moieties, preferably by a nitrile or an aroyl, an ester,
an N-substituted amide group or a short brominated alkyl chain
(Jampilek, 2014). The position C(3) is most often substituted by
short alkyl chain (e.g., CH3, CF3) or phenyl. Substitution of C(6)
or C(7) of QdNOs by Cl, F, CF3, or OCH3 is also advantageous.
When the nitrile moiety is C(2) substituent, substituents in
other positions should not be so much electron-withdrawing. It
can be concluded that generally lipophilic and mostly electron-
withdrawing substituents are preferred.
Although it has been generally accepted that QdNOs are
prodrugs, transport forms of agents that are reduced to active
metabolites in the body, the modes of actions of QdNOs
are still indistinct. The research of the mechanism of actions
of QdNOs is in progress, pushing the development of new
compounds with more efficient potentials and less harmful
effects. Though modes of antitumoral and antibacterial actions
of QdNOs are comparatively clear, there are still some puzzles
need to be explained. First, the enzyme(s), reducing and
activating QdNOs to produce the free radicals, need to be
identified. Since free radicals are short-lived, the location of
enzyme(s) might indicate the subcellular or molecular target(s)
of the drugs. Second, the type of free radical(s) and how
they attack DNA or other target(s) should be identified and
elucidated. Third, the network of the drug action and the
interactions between drugs and organisms should be fully
studied. Fortunately, the genomic and proteomic techniques have
become effective ways to investigate drug action pathway and
discover new drug targets. Furthermore, the research of the
mode of action of QdNOs will provide clues to the study of
drug resistant and toxicological mechanism, and guide more
effective medication of QdNO drugs, e.g., drug combination
therapy. For those modes of actions of QdNOs which are still
vague, such as antiprotozoal and anticandida activity, researchers
are suggested to investigate them according to the already
known mechanisms and the SAR of QdNOs combined with
new research tools, such as omics technology and 3D-QSAR.
A deeper knowledge of the molecular targets of QdNOs is
required for the development of new and more specific drugs
through a rational design strategy to avoid undesirable side
effects.
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